ADVANZ PHARMA: European Commission approves Exblifep (cefepime and enmetazobactam )to treat complicated urinary tract infections, pyelonephritis, hospital-acquired pneumonia ,and ventilator-associated pneumonia.- Advanz Pharma

Advanz Pharma Holdco Limited a UK headquartered global pharmaceutical company with a strategic focus on speciality, hospital, and rare disease medicines in Europe, Canada, and Australia, and Allecra Therapeutics , a biopharmaceutical company developing novel therapies to combat antibiotic resistance, announced that the EC granted a marketing authorization for Exblifep an antibiotic fixed-dose combination of cefepime and enmetazobactam.